640294-72-0Relevant academic research and scientific papers
Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic Optimization of Inhibitors of Hepatitis C Virus NS3/4A Protease
Andrews, David M.,Barnes, Michael C.,Dowle, Mike D.,Hind, S. Lucy,Johnson, Martin R.,Jones, Paul S.,Mills, Gail,Patikis, Angela,Pateman, Tony J.,Redfern, Tracy J.,Robinson, J. Ed,Slater, Martin J.,Trivedi, Naimisha
, p. 4631 - 4634 (2003)
(Matrix presented) In this, the second of two Letters, the optimization of the pyrrolidine-5,5-trans-lactam template (exemplified by 1a) as a mechanism-based inhibitor of hepatitis C NS3/4A protease is described. Right Boxn analysis of cassette dosing screening pharmacokinetic data was used to rapidly categorize the compounds. GW0014 (compound 4d) emerged as the compound displaying an optimal balance of biochemical and replicon potency, along with low i.v. clearance in the dog.
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 Urea Leads to Potent Intracellular Inhibitors of Hepatitis C Virus NS3/4A Protease
Slater, Martin J.,Amphlett, Elizabeth M.,Andrews, David M.,Bamborough, Paul,Carey, Seb J.,Johnson, Martin R.,Jones, Paul S.,Mills, Gail,Parry, Nigel R.,Somers, Donald O'N.,Stewart, Alan J.,Skarzynski, Tadeusz
, p. 4627 - 4630 (2007/10/03)
(Matrix presented) In this, the first of two Letters, we describe how a P3/P4 urea linking unit was used to greatly enhance the biochemical and replicon potency of inhibitors based upon the pyrrolidine-5,5-trans-lactam template. Compound 7b demonstrated a
